Intermune Inc (ITMN) 73.74 $ITMN
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action
PR Newswire - Fri Sep 19, 8:51PM CDT
InterMune, Inc. (Nasdaq: ITMN) today announced that it entered into a Memorandum of Understanding to settle the litigation in the Delaware Court of Chancery relating to the Agreement and Plan of Merger dated as of August 22, 2014, among Roche Holdings, Inc., Klee Acquisition Corporation and InterMune, Inc. As one term of the Memorandum of Understanding, the Company agreed to make certain supplemental disclosures set forth in the attached exhibit reflecting the amendment to the Company's Schedule 14D-9 to be filed with the Securities and Exchange Commission on the morning of Monday, September 22, 2014.
Why Roche (RHHBY) Stock Is Up Today
at The Street - Tue Sep 16, 2:02PM CDT
CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
Market Activity, Upcoming Events, Earnings Release Schedule, and Investment in New Business Facilities - Research Reports on BlackRock, InterMune, JB Hunt, United Parcel Service and Exelon
PR Newswire - Mon Sep 15, 7:45AM CDT
Today, Analysts Review released its research reports regarding BlackRock, Inc. (NYSE: BLK), InterMune, Inc. (NASDAQ: ITMN), JB Hunt Transport Services Inc. (NASDAQ: JBHT), United Parcel Service, Inc. (NYSE: UPS) and Exelon Corporation (NYSE: EXC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6457-100free.
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015
PR Newswire - Fri Sep 05, 7:00AM CDT
InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible Senior Notes Due 2015:
Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities.
Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune" in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court.
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action
PR Newswire - Fri Sep 19, 8:51PM CDT
InterMune, Inc. (Nasdaq: ITMN) today announced that it entered into a Memorandum of Understanding to settle the litigation in the Delaware Court of Chancery relating to the Agreement and Plan of Merger dated as of August 22, 2014, among Roche Holdings, Inc., Klee Acquisition Corporation and InterMune, Inc. As one term of the Memorandum of Understanding, the Company agreed to make certain supplemental disclosures set forth in the attached exhibit reflecting the amendment to the Company's Schedule 14D-9 to be filed with the Securities and Exchange Commission on the morning of Monday, September 22, 2014.
Why Roche (RHHBY) Stock Is Up Today
at The Street - Tue Sep 16, 2:02PM CDT
CEO Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN) was "exceptional" and not a sign of more ambitious plans for major acquisitions.
Why Anxious Investors' Pressure Could Push Small Cap Stocks Lower
at The Street - Tue Sep 16, 1:09PM CDT
Small-cap stocks are experiencing selling pressure this week as volatility rises as world event prey on investor uncertainty.
Market Activity, Upcoming Events, Earnings Release Schedule, and Investment in New Business Facilities - Research Reports on BlackRock, InterMune, JB Hunt, United Parcel Service and Exelon
PR Newswire - Mon Sep 15, 7:45AM CDT
Today, Analysts Review released its research reports regarding BlackRock, Inc. (NYSE: BLK), InterMune, Inc. (NASDAQ: ITMN), JB Hunt Transport Services Inc. (NASDAQ: JBHT), United Parcel Service, Inc. (NYSE: UPS) and Exelon Corporation (NYSE: EXC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6457-100free.
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
InterMune Announces Anticipated Fundamental Change for 5.00% Convertible Senior Notes Due 2015
PR Newswire - Fri Sep 05, 7:00AM CDT
InterMune, Inc. (Nasdaq: ITMN) today provided the following notice to the indenture trustee and holders of its outstanding 5.00% Convertible Senior Notes Due 2015:
Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities. Roche's Cobas 6800/8800 Testing Systems Launched - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:55PM CDT
Roche (RHHBY) announced that its cobas 6800/8800 systems -- two integrated and fully automated molecular testing systems for blood and plasma donor screening are commercially available in markets which accept the CE mark.
INTERMUNE SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Against InterMune, Inc. in Connection With Sale of Company to Roche Holding AG -- ITMN
GlobeNewswire - Wed Sep 03, 4:40PM CDT
The Law Offices of Vincent Wong notifies investors of claims of breaches of fiduciary duty against the Board of Directors of InterMune, Inc. (Nasdaq:ITMN) ("InterMune"
in connection with the sale of the Company to Roche Holding AG. A complaint was filed in California state court. 
